Decreased expression of ErbB2 on left ventricular epicardial cells in patients with diabetes mellitus.
Joanne T de Kay, Joshua Carver, Bailey Shevenell...
https://pubmed.ncbi.nlm.nih.gov/35609807Actively Recruiting
Age: 18Years +
All Genders
ID02820233
Isolation and Characterization of ERBB Expressing Human Heart Progenitor Cells
Led by Douglas B. Sawyer · Updated on 2025-04-03
80
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
Sponsors
D
Douglas B. Sawyer
Lead Sponsor
M
MaineHealth
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating the role of the epidermal growth factor (EGF) receptor family and EGF family ligands in regulating non-heart muscle cells taken from the human heart. This study focuses on how Neuregulin-1β (NRG) and ERBB receptors contribute to heart development and maintenance, particularly in progenitor cells found in adult human hearts. The study aims to enhance understanding of EGF/NRG/ERBB signaling in heart disease and heart failure. Participants are individuals diagnosed with severe coronary artery disease who are scheduled for coronary artery bypass surgery. During surgery, a small heart tissue biopsy is collected. The collected cells are processed in the laboratory using flow cytometry and cell culture techniques to analyze ERBB receptor expression and understand how NRG and EGF regulate these progenitor cells. Participants will undergo surgery during which the biopsy is taken. Laboratory assessments include counting the number of highly proliferative cell clones up to 14 days after isolation and measuring ERBB receptor expression on these clones. The study observes how these cells respond biologically to NRG and EGF, contributing valuable data to heart disease research. Participation duration depends on surgery scheduling and tissue analysis timelines.
CONDITIONS
Brief Title
Studies of Neuregulin/ERBB Signaling in Human Heart
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of severe coronary artery disease scheduled to undergo coronary artery bypass surgery
You will not qualify if you...
- Less than 18 years of age
- Unwilling or unable to provide informed consent
- Known active myocarditis
- Hypertrophic cardiomyopathy
- Constrictive pericarditis or other significant pericardial disease
- Severe pulmonary hypertension
- Significant renal impairment (Creatinine > 2.5 mg/dL)
- Severe ventricular arrhythmias
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Surgery and Immediate Post-operative Care
Duration - Day of surgery
Participants undergo scheduled heart surgery during which a small biopsy is taken from their heart for study purposes.
1 surgical visit (in-person)
Observational Monitoring
Duration - Up to 14 days from biopsy
Biopsied heart cells are analyzed in the laboratory to understand their biology regulated by Neuregulin and EGF without further participant intervention.
No additional visits required
Trial Site Locations
Total: 1 location
1
Maine Medical Center
Portland, Maine, United States, 04102
Actively Recruiting
Loading map...
Research Team
J
Joanne Burgess, RN
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
ErbB2 promotes endothelial phenotype of human left ventricular epicardial highly proliferative cells (eHiPC).
Sergey Ryzhov, Michael P Robich, Daniel J Roberts...
https://pubmed.ncbi.nlm.nih.gov/29291395Prolonged Cardiopulmonary Bypass is Associated With Endothelial Glycocalyx Degradation.
Michael Robich, Sergey Ryzhov, Doreen Kacer...
https://pubmed.ncbi.nlm.nih.gov/32199337